Q32 Bio Inc. QTTB
Q32 Bio Inc. (Nasdaq: QTTB) is a dermatology drug developer. Its lead program, Bempikibart (ADX-914), is in Phase 2 for Alopecia areata (AA). Its next catalyst on record is Bempikibart (ADX-914): Registration-directed trial initiation (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Bempikibart (ADX-914) — Registration-directed trial initiation (H1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Bempikibart (ADX-914) | Alopecia areata | antibody | Phase 2 |
| ADX-914-XL | Not specified | antibody | Pre-clinical |
Recent results and decisions
- positive Q32 Bio presented additional 36-week results and 16-week off-drug findings from Part B of SIGNAL-AA showing a mean SALT score reduction of 35.3% and 40.0% SALT-20 response with robust durability off-drug.
In Part B at Week 36, bempikibart demonstrated clinically meaningful efficacy data on the primary endpoint with a mean percent reduction in Severity of Alopecia Tool (SALT) score from baseline of 35.3% in the prespecified modified intent-to-treat (mITT) analysis.
Filing - Jul 13, 2026positive Positive 36-week topline: mean SALT reduction 35.3% (mITT); SALT-20 in 40.0% (10/25) mITT and 30.3% (10/33) ITT; no treatment-related SAEs or Grade>=3 AEs (open-label, n=33).
Mean percent reduction in SALT score from baseline of 35.3% in the mITT analysis.
Filing - May 5, 2026started First patient dosed in the open-label extension of SIGNAL-AA Part B.
The first patient has been dosed in the OLE portion of Part B.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 dermatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.